Cumberland Pharmaceuticals ( CPIX)

Drug/indication:Acetadote for non-acetaminophen acute liver failure

Approval decision date: December 2010

Recent stock performance: At $4.92, stock is trading at its lows for the year.

The FDA review was extended three months beyond its original August approval date.

Orexigen Therapeutics ( OREX)

Drug/indication: Contrave for obesity

FDA advisory panel: Dec. 7, 2010

Approval decision date: Jan. 31, 2011

Recent stock performance: At 4.73, the stock is starting to lift off its July low of $3.81.

Orexigen is the third company, after Vivus and Arena, to bring its obesity drug in front an FDA advisory panel.

Human Genome Sciences

Drug/indication: Benlysta for lupus

Approval decision date: Dec. 9, 2010

If approved, Benlysta would be the first new drug for lupus patients in 50 years. GlaxoSmithKline will co-market Benlysta.

If you liked this article you might like

Insider Trading Alert - MAR, EVER And VVUS Traded By Insiders

Insider Trading Alert - MDSO, KAI And VVUS Traded By Insiders

Insider Trading Alert - OMAM, CBOE And VVUS Traded By Insiders

Insider Trading Alert - SBCF, VVUS And ACN Traded By Insiders

Vivus (VVUS) Strong On High Relative Volume Today